cytarabine has been researched along with Cancer, Second Primary in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (26.98) | 18.2507 |
| 2000's | 49 (38.89) | 29.6817 |
| 2010's | 28 (22.22) | 24.3611 |
| 2020's | 15 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, KJ; Farrar, JE; Federico, SM; Hu, Y; Lei, S; Lewis, S; Nichols, KE; Onciu, M; Ribeiro, RC; Rubnitz, JE; Salek, M; Takemoto, CM; Triplett, BM; Wlodarski, MW; Zhang, J | 1 |
| Burnett, A; Dennis, M; Hills, R; Kjeldsen, L; Russell, N | 1 |
| Faderl, S; Goldberg, SL; Lancet, JE; Lin, TL; Newell, LF; Ryan, RJ; Uy, GL; Wieduwilt, MJ | 1 |
| Chan, O; Deutsch, Y; Eatrides, J; Jain, AG; Komrokji, R; Kuykendall, A; Lancet, J; Lee, D; Padron, E; Sallman, D; Sweet, K; Talati, C | 1 |
| Abousaud, A; Orellana-Noia, V | 1 |
| Asubonteng, K; Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Prebet, T | 1 |
| Matthews, A; Pratz, KW | 1 |
| Ball, B; Baron, J; Famulare, C; Fazal, S; Goldberg, AD; Griffiths, EA; Przespolewski, A; Sanikommu, SR; Stahl, M; Sweet, K; Talati, C; Thompson, JE; Thota, S; Vachhani, P; Waksal, J; Wang, ES | 1 |
| Hem, S; Kohan, D; Otero, V; Pappolla, A; Rugiero, M; Sosa-Albacete, F; Zurru-Ganen, MC | 1 |
| Au-Yeung, R; Kwong, YL; Sim, JPY | 1 |
| Kasner, MT | 1 |
| Alati, C; Audisio, E; Bertani, G; Bilio, A; Caizzi, M; Candoni, A; Carnevale-Schianca, F; Cerrano, M; Cignetti, A; Clavio, M; D'Ardia, S; Dargenio, M; Ferrara, F; Fianchi, L; Fracchiolla, N; Galimberti, S; Gottardi, M; Grimaldi, F; Guolo, F; Gurreri, C; Lemoli, RM; Minetto, P; Morselli, M; Musto, P; Pagano, L; Pasciolla, C; Pavesi, F; Pietrantuono, G; Rizzuto, G; Rondoni, M; Rossi, G; Scappini, B; Scattolin, AM; Tafuri, A; Zappasodi, P | 1 |
| Altmann, B; Banos, A; Bay, JO; Bilger, K; Bouabdallah, K; Braulke, F; Cartron, G; Damaj, G; de Leval, L; Delmer, A; Dreger, P; Dreyling, M; Friedrichs, B; Gaulard, P; Gisselbrecht, C; Glass, B; Gyan, E; Haenel, M; Jaccard, A; Keller, U; Kroschinsky, F; Lamy, T; Leclerc, M; Lindemann, W; Metzner, B; Milpied, N; Nickelsen, M; Poeschel, V; Reimer, P; Rosenwald, A; Roussel, M; Sanhes, L; Schmitz, N; Sibon, D; Tournilhac, O; Truemper, L; Viardot, A; Wagner, E; Wilhelm, M; Wulf, G; Ziepert, M | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| Chan, G; Cortes, JE; Fiedler, W; Heuser, M; Hoang, CJ; Leber, B; Ma, WW; Merchant, A; Montesinos, P; O'Brien, T; O'Connell, A; Papayannidis, C; Pérez-Simón, JA; Sekeres, MA; Smith, BD; Zeremski, M | 1 |
| Plesa, A; Thomas, X | 1 |
| Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Ryan, RJ; Uy, GL | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Cen, J; Chen, S; Pan, J; Shao, H; Wu, C; Yang, Q | 1 |
| Amrolia, P; Breslin, P; Cummins, M; De La Fuente, J; Gassas, A; Gibson, B; Hiwarkar, P; Hough, R; James, B; Lawson, S; Patrick, K; Petterson, T; Potter, M; Shenton, G; Sivaprakasam, P; Skinner, R; Slatter, M; Veys, P; Vora, A; Wynn, R | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Banerjee, K; Bixby, DL; Chiarella, M; Cortes, JE; Hoering, A; Hogge, D; Kolitz, JE; Lancet, JE; Lin, TL; Louie, AC; Medeiros, BC; Newell, LF; Ritchie, EK; Ryan, DH; Schiller, GJ; Solomon, SR; Stone, RM; Strickland, SA; Stuart, RK; Uy, GL; Wieduwilt, MJ | 1 |
| Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L | 1 |
| Shea, LK; Uy, GL | 1 |
| Advani, A; Elson, P; Kalaycio, M; Kendeigh, C; Maciejewski, JP; Mohan, S; Mukherjee, S; Ornstein, MC; Saunthararajah, Y; Sekeres, MA; Tiu, RV | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Aldayel, AS; Konoplev, S; Medeiros, LJ; Rich, A; Sun, J; Yin, CC | 1 |
| Cabanillas, F; Cheah, CY; Chihara, D; Fayad, LE; Goy, A; Hagemeister, FB; Kantarjian, H; Kwak, LW; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, ML; Westin, JR; Younes, A | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Bolster, L; Brandwein, J; Ghosh, S; Hamilton, M; Larratt, L; Liew, E; Mant, M; Patterson, JM; Peters, A; Ritchie, B; Saini, L; Sandhu, I; Turner, R; Wu, C; Zhu, N | 1 |
| Amin, K; Barbarotta, L; Gore, SD; Kasberg, S; Kim, TK; Podoltsev, NA; Prebet, T; Roche, K; Stahl, M; Xu, ML; Zeidan, AM | 1 |
| Chen, JY; Lu, C; Tang, X; Wang, JW | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Anagnostopoulos, I; Kanz, L; Pezzutto, A; Subklewe, M; Weidmann, E; Weisel, KC | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Alexander, C; Bashford, J; Jefferies, PD; Lee, GA; Whitehead, K | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S | 1 |
| Borthakur, G; Cortes, JE; Estey, EE; Faderl, S; Jain, N; Kantarjian, H; Lin, E; O'Brien, S; Pierce, S; Ravandi, F | 1 |
| Betancourt-García, RD; Castro, J; Fernández, AC; Fradera, J; López-Enríquez, A; Pacheco, E | 1 |
| Abadjian, GA; Aftimos, PG; El Karak, FR; Ghosn, MG; Haddad, AC; Nassar, MN | 1 |
| Cotta, CV; Khan, G; Pohlman, B; Sweetenham, J; Wesolowski, R | 1 |
| FUJIMOTO, H; HIASA, Y; HORIUCHI, N; KIMURA, S; MASUDA, K; MATSUSHITA, T; NAKAMURA, S; SHICHIJO, K; SHINOMIYA, S; TAKAHASHI, K; TAKEICHI, T; TAMAKI, Y; YAMANAKA, C | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Henze, G; Kremens, B; Lakomek, M; Reinhardt, D; Stary, J; Urban, C; Zimmermann, M | 1 |
| Artz, A; Daugherty, CK; Godley, LA; Green, M; Larson, RA; Le Beau, MM; Lin, S; Njiaju, UO; Odenike, O; Rich, ES; Stock, W; Van Besien, K; Weiner, H; Zhang, Y | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Artz, A; Campbell, NP; Daugherty, C; Gajria, D; Godley, LA; Green, M; Gurbuxani, S; Huo, D; Hyjek, E; Larson, RA; Larson, SM; Odenike, O; Sipkins, D; Stock, W; Thirman, M; Van Besien, K; Weiner, H; Zhang, Y | 1 |
| Bain, BJ; Innes, A; May, PC; Pavlů, J | 1 |
| Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM | 1 |
| Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W | 1 |
| Brice, P; Brousse, N; Casasnovas, O; Delarue, R; Delmer, A; Haioun, C; Hermine, O; Lefrere, F; Ribrag, V; Salles, G; Tilly, H; Van Hoof, A | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Hamaguchi, H; Morita, Y; Nagata, K; Yamamoto, K | 1 |
| Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ | 1 |
| Das, M; Gmori, M; Konstantini, S; Nagler, A; Panigrahi, S; Slavin, S; Stagler, D | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Deckert, M; Montesinos-Rongen, M; Pels, H; Schaller, C; Schlegel, U; Van Roost, D; Wiestler, OD | 1 |
| Gandhok, N; Sartor, O | 1 |
| Bayraktaroglu, T; Borazan, A; Demircan, N; Ozdemir, H; Ozer, T; Savranlar, A; Ustündag, Y | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Camitta, BM; Casper, JT; Eapen, M; Keever-Taylor, CA; Margolis, DA; Murray, KJ; Pierce, KL; Talano, JM | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW | 1 |
| Hatoum, HA; Hudaib, AR; Mahfouz, RA; Otrock, ZK; Shamseddine, AI; Taher, AT | 1 |
| Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
| Huang, Q; Pitman, SD | 1 |
| Gill, DS; Hawley, CM; Marlton, PV; Norris, D; Tey, SK | 1 |
| Caira, M; Fianchi, L; Gianfaldoni, G; Leone, G; Leoni, F; Pagano, L; Rutella, S; Scardocci, A; Storti, S; Valentini, CG; Voso, MT | 1 |
| Brand, R; Dreger, P; Michallet, M | 1 |
| Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B | 1 |
| Fujimoto, J; Kikuchi, A; Kumagai, M; Mori, T; Okimoto, Y; Sunami, S; Tsuchida, M | 1 |
| Asou, N; Hata, H; Horikawa, K; Hoshino, K; Matsuno, F; Mitsuya, H; Miyake, H; Nosaka, K; Takatsu, N; Tatetsu, H | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL | 1 |
| Andrews, R; Begent, RH; Boshoff, C; Holden, L; Newlands, ES; Oliver, RT; Ong, J; Rustin, GJ; Skelton, M | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Behm, FG; Boyett, JM; Hancock, ML; Krance, RA; Mahmoud, HH; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Sandlund, JT | 1 |
| Anastasi, J; Hayashi, Y; McGavran, L; Nucifora, G; Roulston, D; Rowley, JD; Rudinsky, R; Tsuchida, M; Zeleznik-Le, N | 1 |
| Amadori, S; Avvisati, G; Cedrone, M; Cimino, G; Mancini, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E | 1 |
| Chessells, JM | 1 |
| Crist, WM; Pratt, CB; Pui, CH; Rivera, GK; Santana, VM | 1 |
| Niitsu, N; Shikoshi, K; Takada, M; Umeda, M | 1 |
| Preisler, H | 1 |
| Bairey, OS; Sandbank, Y; Shaklai, M | 1 |
| Akatsuka, J; Furukawa, T; Nakazawa, S; Nishimura, K; Ohira, M; Okawa, Y; Sugita, K; Tsuchida, M | 1 |
| Ikeda, K; Inoo, M; Murao, S; Murata, M; Nagai, M; Sasaki, K; Takahara, J; Tasaka, T; Tokuda, M | 1 |
| Cleary, ML; Davis, RE; Kamel, OW; Soslow, RA; Warnke, RA | 1 |
| Benaim, E; Crist, WM; Hudson, MM; Liu, Q; Pui, CH; Ribeiro, RC; Rivera, GK | 1 |
| Azar, N; Binet, JL; Boccaccio, C; Charlotte, F; Gabarre, J; Gentilini, M; Gonzalez, H; Jouan, M; Leblond, V; Sutton, L | 1 |
| Chaibi, P; de Revel, T; Dombret, H; Gardin, C; Micléa, JM; Nédellec, G; Rousselot, P; Turlure, P | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Goldberg, SL; Klumpp, TR; Mangan, KF; Ming, PL; Mullaney, MT; Rao, PN; Redei, I | 1 |
| Higuchi, T; Mori, H; Omine, M; Saito, F | 1 |
| Alyea, E; Anderson, K; Bartlett-Pandite, L; Fairclough, D; Fisher, D; Freedman, A; Freeman, A; Marcus, K; Mauch, P; Murray, C; Nadler, L; Ritz, J; Robertson, M; Schlossman, RL; Soiffer, RJ; Stone, R | 1 |
| Appelbaum, FR; Chen, IM; Godwin, J; Head, DR; Kopecky, KJ; Leith, CP; McConnell, T; Slovak, ML; Willman, CL | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Hengge, UR; Schultewolter, T; Uppenkamp, T | 1 |
| Asami, K; Eguchi, H; Hatae, Y; Hirota, T; Iwai, A; Katano, N; Koizumi, S; Kono, Y; Matusita, T; Miyawaki, T; Mugisima, H; Nakayama, M; Nisikawa, K; Osima, K; Sekine, I; Simokawa, T; Suzumiya, J; Tanaka, A; Tsuchiya, T; Tsurusawa, M; Utumi, J; Yamamoto, Y; Yamamura, Y; Yanase, T; Yokota, S | 1 |
| Astori, C; Bernasconi, C; Bernasconi, P; Lazzarino, M; Orlandi, E | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Ariyoshi, K; Kameda, N; Kamei, T; Katsuki, K; Shinohara, K; Takeda, K; Yamada, T | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Campbell, LJ; Ellims, PH; Estey, EH; Juneja, SK; Prince, HM; Seymour, JF | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Bauduer, F; Capdupuy, C; Dastugue, N; Ducout, L; Renoux, M | 1 |
| Eden, OB; Gibson, B; Hann, I; Hill, F; Kinsey, S; Lilleyman, J; Mitchell, C; Richards, S; Vora, A | 1 |
| Aoyagi, A; Aoyagi, M; Arai, H; Arai, Y; Furusawa, S; Gunnji, H; Handa, T; Inoue, F; Kawagoe, Y; Kitsukawa, Y; Nakamura, Y; Saito, K; Tadokoro, J; Takahashi, W; Tsurumi, S; Waga, K; Yamamoto, K | 1 |
| Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Douglas, R; Michael, B; Nabil, S; Thomas, F | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
| Akiyoshi, K; Eguchi, H; Hara, T; Inada, H; Ishii, E; Koga, H; Matsuzaki, A; Miyazaki, S; Nagatoshi, Y; Nakayama, H; Nibu, K; Okamura, J; Take, H; Tamai, Y; Yanai, F | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Aoki, S; Imai, K; Kazama, Y; Shimizu, H; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Fujimaki, K; Fujisawa, S; Ishigatsubo, Y; Kanamori, H; Tanaka, M; Tomita, N; Yamaji, S | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Kakishita, E; Mori, A; Okada, M; Okamoto, T; Takatsuka, H; Wakae, T | 1 |
| Ballard, ET; Huang, FS; Stern, LE; Warner, BW; Zwerdling, T | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Brito, G; Fernandez, T; Klumb, C; Land, MG; Maradei, S; Otero, L; Pombo-de-Oliveira, MS; Silva, ML; Veith, M | 1 |
| Alberto, P; Mermillod, B; Zulian, GB | 1 |
| Hempling, RE; Piver, MS; Sprance, HE | 1 |
22 review(s) available for cytarabine and Cancer, Second Primary
| Article | Year |
|---|---|
Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System; Central Nervous System Neoplasms; Cytarabine; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasms, Second Primary; Rituximab | 2022 |
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Choosing induction chemotherapy in therapy-related acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Neoplasms, Second Primary | 2019 |
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Brain; Cerebral Hemorrhage; Cytarabine; Fatal Outcome; Humans; Hydroxamic Acids; Idarubicin; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mast Cells; Middle Aged; Neoplasms, Second Primary; Neoplastic Stem Cells; Opportunistic Infections; Prostatectomy; Prostatic Neoplasms; Vorinostat | 2014 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Synergism; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Monosomy; Neoplasms, Second Primary; Translocation, Genetic; Tretinoin | 2009 |
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic | 2012 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acinar Cell; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parotid Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survivors; Sweat Gland Neoplasms; Vincristine; Whole-Body Irradiation | 2008 |
Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction | 2007 |
Granular acute lymphoblastic leukemia: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Cytoplasmic Granules; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Methotrexate; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome; Vincristine | 2007 |
Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Cell; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Liver Neoplasms; Lymphoma, T-Cell; Methotrexate; Middle Aged; Neoplasms, Second Primary; Postoperative Complications; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Splenic Neoplasms; Urinary Bladder Neoplasms; Vesico-Ureteral Reflux; Vincristine | 2008 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasms, Second Primary; Oncogenes; Topoisomerase II Inhibitors; Translocation, Genetic | 1995 |
Central nervous system directed therapy in acute lymphoblastic leukaemia.
Topics: Adrenal Cortex Hormones; Adult; Child; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Growth Disorders; Humans; Injections, Spinal; Leukemic Infiltration; Male; Meninges; Mental Disorders; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Quality of Life; Radiation Injuries; Risk Factors; Survival Rate; Survivors; Treatment Outcome | 1994 |
Epipodophyllotoxins in the treatment of childhood cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide | 1994 |
Poor prognosis acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Neoplasms, Second Primary; Neoplastic Stem Cells; Preleukemia; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Failure | 1993 |
Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Neuroendocrine; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Prognosis; Treatment Outcome | 1999 |
Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Growth Disorders; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Male; Methotrexate; Myelodysplastic Syndromes; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Survivors; Treatment Outcome; Vincristine | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
29 trial(s) available for cytarabine and Cancer, Second Primary
| Article | Year |
|---|---|
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Remission Induction; Vidarabine | 2022 |
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.
Topics: Aged; Allografts; Compassionate Use Trials; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2020 |
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Topics: Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Risk; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2021 |
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Phenylurea Compounds; Survival Analysis; Treatment Outcome | 2021 |
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quality of Life; Survival Analysis | 2021 |
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary | 2018 |
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Vincristine | 2016 |
Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Recurrence; Survival Analysis; Treatment Outcome; Tretinoin | 2010 |
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Myeloid Cells; Neoplasms, Second Primary; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Kidney Diseases; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Neoplasms, Second Primary; Prognosis; Remission Induction; Risk | 2008 |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Humans; Infant; Lymphoma, B-Cell; Methotrexate; Neoplasms, Second Primary; Recurrence; Survival Analysis; Treatment Outcome | 2008 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 1994 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Humans; Infant; Karyotyping; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 1995 |
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Prospective Studies; Remission Induction | 1997 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infections; Leukemia; Life Tables; Lymphocyte Depletion; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Risk; Survival Analysis; T-Lymphocyte Subsets; Transplantation, Homologous; Treatment Outcome | 1997 |
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Double-Blind Method; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recombinant Proteins | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
[Treatment of children with non-Hodgkin's lymphoma with CCLSG NHL 855/890 protocols long-term outcome and incidence of secondary malignancies].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydrocortisone; Infant; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Prednisolone; Remission Induction; Treatment Outcome; Vincristine | 1998 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infections; Male; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2000 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
75 other study(ies) available for cytarabine and Cancer, Second Primary
| Article | Year |
|---|---|
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
Topics: Adolescent; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Prospective Studies | 2022 |
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Retrospective Studies | 2022 |
Optimizing outcomes in secondary AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary | 2023 |
[Primary neurolymphomatosis in the cauda equina as the initial symptom of human immunodeficiency virus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cauda Equina; Cytarabine; Gait Disorders, Neurologic; Humans; Kidney Neoplasms; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasms, Second Primary; Neurolymphomatosis; Rituximab | 2019 |
Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Topics: Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Daunorubicin; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Postoperative Complications; Programmed Cell Death 1 Receptor; Protoporphyria, Erythropoietic; Recurrence; Remission Induction; Virus Activation; Young Adult | 2020 |
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Neoplasms, Second Primary; Treatment Outcome | 2019 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2021 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Binding Factor; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Myosin Heavy Chains; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Transplantation, Autologous | 2017 |
High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Remission Induction; Salvage Therapy; Survival Analysis; United Kingdom; Vidarabine | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Statistical; Neoplasms, Second Primary; Patient Outcome Assessment; Prognosis; Risk Factors; Treatment Outcome | 2014 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
Topics: Aged, 80 and over; Antibodies, Bispecific; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Transitional Cell; Cytarabine; Female; Humans; Lymphoma, B-Cell; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms; Vincristine | 2016 |
Sequential development of peripheral t-cell lymphoma post immunochemotherapy of diffuse large B cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Cytarabine; Epstein-Barr Virus Infections; Etoposide; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Herpesvirus 4, Human; Humans; Immunohistochemistry; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Neoplasms, Second Primary; Polymerase Chain Reaction; Prednisone; Radiotherapy, Adjuvant; Receptors, Antigen, T-Cell; Rituximab; Tomography, X-Ray Computed; Tongue | 2017 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Middle Aged; Neoplasms, Second Primary; Virus Latency | 2008 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
Life-threatening conjunctival presentation of myeloid sarcoma.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Conjunctival Neoplasms; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Sarcoma, Myeloid; Skin Neoplasms | 2008 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2009 |
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Analysis; Translocation, Genetic | 2009 |
Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation.
Topics: Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 8; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Trisomy | 2010 |
Successful treatment of Hodgkin lymphoma and acute leukemia.
Topics: Adult; Biopsy; Bone Marrow Cells; Cytarabine; Hodgkin Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Remission Induction | 2010 |
Multiple hepatocellular carcinomas developed 15 months after commencement of chemotherapy for elderly acute myelogenous leukemia.
Topics: Aclarubicin; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Hemochromatosis; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Time Factors | 2009 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Erythropoiesis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Vincristine | 2012 |
[Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myelomonocytic, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 2002 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous | 2002 |
Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Immunosuppressive Agents; Injections, Spinal; Leukemia, Monocytic, Acute; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parietal Lobe; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2003 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Base Sequence; Breast Neoplasms; Clone Cells; Combined Modality Therapy; Cytarabine; DNA, Neoplasm; Embryonal Carcinoma Stem Cells; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Germinal Center; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Methotrexate; Molecular Sequence Data; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neoplastic Stem Cells; Parietal Lobe; Remission Induction; Sequence Alignment; Sequence Homology, Nucleic Acid; Supratentorial Neoplasms; Temporal Lobe | 2004 |
Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Goserelin; Humans; Immunocompromised Host; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Neutropenia; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Sepsis; Tosyl Compounds; Vincristine | 2004 |
A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Epidural Space; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Sarcoma, Myeloid; Spinal Neoplasms; Thoracic Vertebrae | 2004 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Donor Selection; Female; Glioblastoma; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation | 2006 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary | 2009 |
Secondary tumours following etoposide containing therapy for germ cell cancer.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Cytarabine; Dactinomycin; Dose-Response Relationship, Drug; Etoposide; Germinoma; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Neoplasms, Second Primary; Testicular Neoplasms; Vincristine | 1995 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Remission Induction; Thioguanine; Translocation, Genetic | 1995 |
[Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 1994 |
Relapse of aggressive myeloma after complete remission in secondary acute leukemia: coincidence or consequence?
Topics: Antigens, CD; Bone Marrow; Cytarabine; Female; HLA-DR Antigens; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence | 1993 |
High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Life Tables; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Risk; Vincristine | 1993 |
[Alterations in morphological and phenotypical features of leukemic cells relapse 7 years after onset in a case of acute non-lymphocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Neoplasms, Second Primary; Prednisolone | 1993 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Mercaptopurine; Methotrexate; Methylprednisolone; Neoplasms, Second Primary; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Remission Induction; Scapula; Spinal Neoplasms; Vincristine | 1996 |
Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Growth Disorders; Humans; Hydrocortisone; Leukemic Infiltration; Life Tables; Male; Meninges; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proportional Hazards Models; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Teniposide; Testis; Time Factors; Treatment Outcome; Vincristine | 1996 |
Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Burkitt Lymphoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Duodenal Neoplasms; Etoposide; Humans; Immunocompromised Host; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Neoplasms, Second Primary; Pancytopenia; Remission Induction; Salvage Therapy; Thigh; Transplantation Conditioning; Vincristine | 1996 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 20; Clone Cells; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Hematopoietic Cell Growth Factors; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm, Residual; Neoplasms, Second Primary; Neoplastic Stem Cells; Prednisone; Procarbazine; Radiotherapy; Recurrence; Transplantation, Autologous; Vinblastine; Vincristine | 1997 |
Three-day standard dose cytarabine could induce an M4Eo patient into complete remission.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Stomach Neoplasms | 1997 |
Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lymphoma, AIDS-Related; Male; Neoplasms, Second Primary; Viral Load | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prednisone; Topoisomerase II Inhibitors; Vincristine | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Leucovorin; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasms, Second Primary; Prednisone; Spinal Cord Neoplasms; Vincristine | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Female; Hospitals, General; Humans; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Survival Analysis | 1999 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Neoplasms, Second Primary; Survival Rate; Treatment Outcome | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Homosexuality, Male; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, AIDS-Related; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Neoplasm Metastasis; Neoplasms, Second Primary; Topoisomerase II Inhibitors | 2001 |
Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.
Topics: Aclarubicin; Adenocarcinoma; Aged; Ampulla of Vater; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholestasis, Extrahepatic; Chromosome Aberrations; Chromosome Disorders; Common Bile Duct Neoplasms; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Pancytopenia; Stomach Neoplasms | 2001 |
Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia.
Topics: Antigens, CD7; Biomarkers, Tumor; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Mercaptopurine; Middle Aged; Neoplasms, Second Primary; Prednisolone; Trisomy | 2001 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Remission Induction; Tretinoin; Vincristine | 2002 |
Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cerebral Infarction; Child; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Humans; Hypertension; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Obesity; Remission Induction; Thioguanine | 2001 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Chromosomes, Human, Pair 11; Cytarabine; Drug Therapy, Combination; Enzyme Inhibitors; Etoposide; Fatal Outcome; Histiocytosis, Langerhans-Cell; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Neoplasms, Second Primary; Nuclear Pore Complex Proteins; Prednisolone; Topoisomerase II Inhibitors; Translocation, Genetic; Vinblastine | 2002 |
ABEP as primary chemotherapy for Hodgkin's disease.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine | 1992 |
Leukemia following cisplatin-based chemotherapy for ovarian carcinoma at Roswell Park.
Topics: Adult; Carcinoma, Papillary; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Neoplasms, Second Primary; Ovarian Neoplasms; Thrombocytopenia | 1992 |